Table 1

Phase II/phase III trials included for analysis

TitleAuthorYear of publicationPhase II/phase III trialProductTender and swollen joints for inclusionPsoriasis criteria for inclusionReference
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialMease PJ et al 2000Phase IIEtanercept (E1)>3Not required 13
Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progressionMease PJ et al 2004Phase IIIEtanercept (E2)>3Not required 14
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Antoni CE et al 2005Phase IIIInfliximab (I1)>5+ elevated CRP (15 mg/L) or ESR (28 mm/h) or morning stiffness >45 minNot required 15
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trialAntoni CE et al 2005Phase IIIInfliximab (I2)>5+ elevated CRP (15 mg/L) or morning stiffness >45 minPsoriasis lesion >2 cm 16
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomised, placebo-controlled trialMease PJ et al 2005Phase IIIAdalimumab>3Active or documented history of psoriasis 17
Golimumab, a new human tumour necrosis factor alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: twenty-four week efficacy and safety results of a randomised, placebo-controlled studyKavanaugh A et al 2009Phase IIIGolimumab>3Psoriasis lesion >2 cm 18
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)Mease PJ et al 2014Phase IIICertolizumab>3+ elevated CRP (7.5 mg/L) or ESR (28 mm/h)Active or documented history of psoriasis 19
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialMcInnes IB et al 2013Phase IIUstekinumab (U1)>5+ CRP (3.0 mg/L)Active or documented history of psoriasis 20
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6 month and 1 year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trialRitchlin C et al 2014Phase IIIUstekinumab (U2)>5 + CRP (6.0, in trial adapted to 3.0 mg/L)Active or documented history of psoriasis 21
Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritisMease PJ et al 2015Phase IISecukinumab (S1)>3Not required 22
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialMcInnes IB et al 2015Phase IIISecukinumab (S2)>3Not required 23
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitorKavanaugh A et al 2014Phase IIIApremilast>3Not required 24
  • CRP, C reactive protein; ESR, erythrocyte sedimentation rate.